USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
IMPEL NEUROPHARMA, INC.
Address:
867 SW SHOREMONT AVE
NORMANDY PARK, WA 98166-3645
EIN:
126305823
DUNS:
827915385
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,389,087.00 4
SBIR Phase II $749,641.00 1

Award List:

CNS targeted delivery of anti-HIV drugs

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$495,245.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This program plans to develop a drug delivery system that provides maximum drug exposure and suppress residual human immunodeficiency virus (HIV)* in the brain and tissues of central nervous system (CNS). The advent of highly active antiretroviral combination… More

Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$69,272.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Rodney J. Ho, Research Scientist
Abstract:
This program plans to develop a drug delivery system that provides maximum oxime drug exposure and improve cholinesterase reactivation in the brain and tissues of central nervous system (CNS) of a warfighter after exposure to organophosphate (OP) poisoning. The greatest need for improvement in… More

Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$749,641.00
Agency:
DOD
Principal Investigator:
John Hoekman, Chief Scientific Officer – (206) 568-1466
Abstract:
Technical Abstract Impel NeuroPharma has developed a novel non-invasive delivery system, the POD device that targets drug to the upper third of the nasal cavity which results in direct and rapid transport of drug to the CNS via the olfactory perineural pathways, effectively bypassing the BBB. In… More

Central Nervous System Delivery of Opioid Peptides

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$149,513.00
Agency:
HHS
Principal Investigator:
John Hoekman – 206-568-1466
Abstract:
DESCRIPTION (provided by applicant): The primary goal of this proposal is to develop opioid peptide aerosol-compatible formulations and an intranasal drug delivery system to deliver mu/delta opioid peptides to the central nervous system (CNS) in effectiveconcentrations as the first step in… More

Tool for non-invasive delivery of central nervous system drug candidates

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$675,057.00
Agency:
HHS
Principal Investigator:
Alan Brunelle – 206-284-8846
Abstract:
DESCRIPTION (provided by applicant): Animal models of disease are transforming preclinical research, allowing critical insights into disease mechanisms and evaluation of new therapeutics. While the utility and availability of animal models in research isswiftly expanding often the research tools… More